Pipeline
Redefining medicine by uniting the intelligence of nature with modern science, we pioneer standardized botanical drug development to navigate the FDA.
CNS Botanical Drug Development Pipeline
Program
Discovery
Optimization
IND-Enabling
Phase 1
Phase 2
Key Programs
AJA001: Novel Cannabinoid Formula (DeFloria™ JV)
Indication: Irritability in Autism Spectrum Disorder
Details: A multi-cannabinoid formula to serve the Autism community with a better and more natural option. Currently, there are only two drugs approved for ASD, both of which have substantial side effects.
AJA002: Novel Tryptamine Formula (Microdose)
Indication: Generalized Anxiety Disorder
Details: Full-spectrum tryptamine formula as a novel antidepressant, solving the problem through safer and more targeted mechanisms of action than traditional antidepressants.
AJA003: Novel Cannabinoid Formula
Indication: Post-Traumatic Stress Disorder
Details: Multi-cannabinoid formula to serve thousands of people suffering from PTSD, including veterans, many of whom have been self-medicating with unregulated products.
AJA004: Novel Tryptamine Formula (Psychedelic Assisted Therapy)
Indication: Undisclosed
Details: Full-spectrum tryptamine formula derived from a unique and lesser-known botanical psychedelic species, offering a different therapeutic experience than investigational new drugs currently in trials.
“The future of medicine is actually millions of years old… the answers to some of the world’s most vexing health care problems are found in the plants, trees, and fungi all around us.”
– Joel Stanley
Full Spectrum Cannabinoid Formulation for Autism Spectrum Disorder
There are 7.7 million individuals with Autism Spectrum Disorder in the US. The ASD community needs better treatments, as only two FDA-approved drugs exist, both with severe side effects.
Through DeFloria™, Inc.—a joint venture between Ajna, Charlotte’s Web™, and BAT—we are developing AJA001, the first FDA-approved full-spectrum botanical cannabinoid extract for Autism Spectrum Disorder. Leveraging CW’s patented genetics and optimized bioavailability, AJA001 aims to improve both symptoms and quality of life.
- Investigational New Drug application on file
- Phase 1 clinical trials complete
- Entering Phase 2 trials
For more information about AJA001 watch DeFloria: A Novel Treatment Option for Autism Spectrum Disorder or visit DeFloria.
Full Spectrum Psilocybin Novel Anti-Depressant
Over 238 million daily use anti-depressants were prescribed in 2020, generating an estimated $18.8B in revenue.
Conventional anti-depressants like SSRIs don’t work for everyone, and grey market microdosing of psilocybin for depression is becoming increasingly popular. A standardized botanical daily microdose will be in high demand.
- Formulation and IP finalized
- Entering Phase 1
Innovation Through Collaboration
Ajna actively seeks partnerships with researchers, clinicians, and biotech innovators to expand our pipeline. Explore opportunities to collaborate at info@ajnabiosciences.com
Patient-Centric
Approach
We are dedicated to transparency and accessibility. For information on clinical trial participation, visit the National Institutes of Health clinical trials database.
“Having a new class of drugs is going to be an exciting new avenue for research and could be a very important alternative to existing treatments. What’s needed are companies like Ajna to bring a pharmaceutical approach to developing these medications and doing the proper research to bring them to market.”
